ADC Review

ADC Review, Journal of Antibody-drug Conjugates welcomes article, commentaries, original research and other manuscripts submissions from established or new authors or researchers - focusing on the technology and strategy underlying the discovery, development, clinical research, regulatory issues, clinical production/commercial manufacturing and clinical use of Antibody-drug Conjugates (ADCs).

To submit an article or manuscript for peer review, please email our at Associate Publisher. Please be sure to submit your manuscript as a Word Document.

All submitted articles, commentaries, original research or other manuscripts will be reviewed by our independent editorial review board, which will advise on matters of content and appropriateness. Accepted articles, commentaries and other manuscripts will be published and included in the peer reviewed section of ADC Review / Journal of Antibody-drug Conjugates. If published, your article will be received by thousands of active researchers, clinicians and executives. The main criteria for guest articles are:

• Topical, appropriateness and timely/current subject matter;
• Written in an accessible, engaging, provocative (op-ed) style;
• 1,000 -6,500 words;
• 6 - 15 references to published peer reviewed articles;
• Author profile(s)/picture)s) – profile no longer than 450 words and author email;
• Include images, illustrations, tables, graphs;
• Manuscripts should not be commercial /or promotional.

• Clinical trials in ADCs
• Disease specific issues related to current and future ADCs
• Current and future state of development
• Site specific conjugation
• How does site of linker attachment influences stability, toxicity, and efficacy of ADCs?
• Selection and identification of new and appropriate targets with the optimal properties for ADC
• Selection of different linkers and payloads
• Efficacy and safety profile of ADC
• Toxicity mechanisms of ADC candidates
• ADME and biodistribution
• PK/PD & PBPK Modeling at various stages of drug discovery and development
• Managing and establishing a harmonized ADC manufacturing supply chain
• Understanding critical elements in the supply chain during clinical/commercial manufacturing
• Critical biological factors in drug discovery and development
• Qualitative and quantitative risk assessments to ensure the safe (clinical) handling of ADCs
• Safety of ADC
• Site Specific Conjugation
• The future of ADCs